Detection, Monitoring & Management of Autoimmune ILD The American Journal of Managed Care has reviewed the approach to patients with ILD; a significant cause of morbidity and mortality in those with SARDs, including RA, SSc, and IIM. https://t.co/xtRfLNyZA6 https://t.co/S9JFlMd9CN

RA at risk for pneumonia & hospitalisation. Pop/ study (41187 RA vs 205935 matched controls). w/ 4yrs F/U, RA had signif. more pneumonia (adj HR 1.73) & hospitaliz (aHR 2.26); higher w/ seropositives (aHR 1.86 & 2.52) & bDMARDs (1.73), but not tsDMARDs (0.93) https://t.co/XJE1FqVqCn

Axial involvement in PsA (axPsA)? study of 581 PsA pts (mean 45 yrs) found 31% w/ SpA-SI joint (SIJ) abnormalities on MRI (MRI-axPsA). MRI-axPsA pts had BM edema(69%), erosions (68%), fat lesions (58%). ~45% w/ Xrays, 29% met Xray mNY criteria for AS (38% +MRI). +MRI assoc w/ https://t.co/MRbs8G3MWq

Study of 246 axSpA (nraxSpA 82, r-axSpA 164) w/ Sxduration 26 yrs. axSpA had more comorbid Dz (^CCI) esp for uveitis (28 vs 1%), IBD (10 v 1%), PsO (10 v 3%)], CVD (7 v 3%), FM (12 v 3%). BUT NO DIFF between r-axSp & nraxSpA for comorbidities https://t.co/0ERLt083yq https://t.co/65x02ZFKTb

How Does Your Garden Grow (9.26.2025) Dr. Jack Cush reviews the news and journal articles from RheumNow. Pool therapy, Fibrosis, NSIE's and what's best for knee OA. https://t.co/JCf9u8Wd4O https://t.co/g0xLmEMLbS

QD clinics on ILD - lessons from the Clinic #3 QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign ILD QD Clinic #3 ILD QD Clinic: Application of the ACR CHEST Guidelines to Two Cases ILD QD Clinic: Progressive RA-ILD Management https://t.co/oYZf9KT9JF

What is IPAF? Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD. https://t.co/ZEexaqoeLK https://t.co/p3Yfv2IkE2

QD Clinic: Stick or twist (when not to change treatment) Dr. Richard Conway, Dublin, discusses a case about when not to change treatment, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/9yQwWTnEtU https://t.co/7k0cSsaPqN

Polypharmacy Impairs Rheumatoid Arthritis Outcomes A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significantly lower treatment responses and more serious adverse events (SAEs). https://t.co/QAJYzHEaFv https://t.co/vUeBsLCYNE

Interstitial lung abnormalities (ILA) are found in 7% of Gen. population, most of whom are asymptomatic, but some will progress to ILD, IPF,and increased risk of lung cancer, etc. Finding incidental ILD appropriate screening monitoring, based on risk factors is indicated. https://t.co/kQbhxTAVTm